MeCure Industries Plc, one of Nigeria’s fastest-growing pharmaceutical manufacturers, has received shareholder approval to expand its capital raising programme from N30 billion to N50 billion, following a financial performance in 2025 that saw profit after tax surge by 177 per cent and revenue climb to its highest level since the company’s listing on the Nigerian Exchange.
The resolution was passed at the company’s third Annual General Meeting held in Lagos, where shareholders also approved a dividend and expressed confidence in the board’s strategy for accelerating expansion across Nigeria and West Africa.
Read also: LCCI, NASD open capital market as alternative funding route for Nigerian SMEs
The 2025 performance that drove the decision
MeCure’s 2025 results represent a decisive break from the earnings pressure of the previous year. Revenue rose 69 per cent to N77.69 billion from N46.03 billion in 2024, while earnings before interest and tax almost doubled to N16.43 billion from N8.28 billion.
Profit after tax climbed 177 per cent to N6.46 billion, reflecting improved operating efficiency, stronger healthcare demand, and the payoff from years of investment in expanded manufacturing capacity that had weighed on earnings during the high-interest-rate period of 2023 and 2024.
Shareholders at the AGM approved a dividend of 32 kobo per ordinary share, amounting to N1.29 billion in total payouts, and pledged to participate in the upcoming N50 billion rights issue. Beyond the financial results, MeCure also secured regulatory approval for 19 new pharmaceutical products across cardiovascular, anti-infective, and metabolic therapy categories during the year, further diversifying its product portfolio.
Read also: Nigeria’s capital inflows hit $10.37bn in Q1 2026, FDI decline signals investment gap
What the N50 billion will fund
Managing Director Vijay Udani said the additional capital would fund strategic expansion projects, strengthen the company’s balance sheet, improve working capital, and enhance operational efficiency in an environment still characterised by elevated financing costs and foreign exchange pressure.
The N50 billion target represents a N20 billion increase from the N30 billion programme initially approved at an extraordinary general meeting in May 2025. MeCure’s growth strategy has been built around filling the supply gap left by the exit of multinational pharmaceutical companies from Nigeria’s prescription drug market, most notably GlaxoSmithKline’s departure, which created openings in antibiotics and other categories that MeCure moved aggressively to occupy.
The company operates a Beta-Lactam manufacturing plant and has expanded its national distribution network to capture the market share that was left behind. With the rights issue, management intends to deepen that position while beginning a more structured push into other West African markets.
Read also: Bumpa, Vendorcredit launch Bumpa Capital to expand credit access for Nigerian SMEs
What it means for Nigerian businesses
MeCure’s trajectory is significant beyond the pharmaceutical sector because it represents a model that runs counter to the narrative of manufacturing decline that has dominated recent economic data. The company expanded through one of the most challenging interest rate and forex environments Nigeria has experienced in a generation, staying the course on capital investment when conditions were difficult and emerging with a stronger market position when conditions began to ease.
For Nigerian SMEs in manufacturing and processing, the story illustrates that deliberate investment in local production capacity, product diversification, and distribution reach can deliver strong returns even when the macroeconomic environment is hostile.
The pharmaceutical sector also carries structural tailwinds that apply more broadly: Nigeria’s growing population, rising healthcare awareness, and government policy pushing for local manufacturing over imports are dynamics that reward producers who build genuine domestic capacity. MeCure’s N50 billion rights issue signals that at least one Nigerian manufacturer believes the structural case for local production has become compelling enough to justify a significant bet on expansion.
